{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polycythemia+Vera", "query": { "condition": "Polycythemia Vera" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 244, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polycythemia+Vera&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T23:18:51.477Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00104923", "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2005-02", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104923" }, { "nct_id": "NCT02226172", "title": "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Glasdegib (PF-04449913)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2014-10-06", "completion_date": "2018-01-31", "has_results": true, "last_update_posted_date": "2019-01-17", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226172" }, { "nct_id": "NCT03373877", "title": "Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "PU-H71", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Samus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-05-24", "completion_date": "2020-03-10", "has_results": false, "last_update_posted_date": "2022-11-15", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 10, "location_summary": "New Haven, Connecticut • New Orleans, Louisiana • Ann Arbor, Michigan + 7 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03373877" }, { "nct_id": "NCT00003406", "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Cancer Treatment Centers of America", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 30, "start_date": "1997-10", "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2013-03-26", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 1, "location_summary": "Zion, Illinois", "locations": [ { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003406" }, { "nct_id": "NCT07379125", "title": "Therapeutic RSK1 Targeting in Myelofibrosis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "PMD-026", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-05-31", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07379125" }, { "nct_id": "NCT04282187", "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Essential Thrombocythemia", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myeloproliferative Neoplasm", "Myeloproliferative Neoplasm, Not Otherwise Specified", "Polycythemia Vera", "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Fedratinib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Pacritinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-03-24", "completion_date": "2026-11-11", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04282187" }, { "nct_id": "NCT01317875", "title": "Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2011-03-31", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 3, "location_summary": "Winter Park, Florida • Baltimore, Maryland • Houston, Texas", "locations": [ { "city": "Winter Park", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01317875" }, { "nct_id": "NCT04054245", "title": "PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis Transformation in Essential Thrombocythemia", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Primary Myelofibrosis" ], "interventions": [ { "name": "LOXL2 Inhibitor PAT-1251", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-07-24", "completion_date": "2019-07-24", "has_results": false, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04054245" }, { "nct_id": "NCT02252159", "title": "Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [], "intervention_types": [], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2544, "start_date": "2014-07-31", "completion_date": "2019-08-03", "has_results": false, "last_update_posted_date": "2021-04-26", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 264, "location_summary": "Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more", "locations": [ { "city": "Green Valley", "state": "Arizona" }, { "city": "Safford", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02252159" }, { "nct_id": "NCT01137825", "title": "Registry of Older Patients With Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Cognitive/Functional Effects", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [], "intervention_types": [], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 3000, "start_date": "2009-09", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-05-21T23:18:51.477Z", "location_count": 7, "location_summary": "Boone, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina + 4 more", "locations": [ { "city": "Boone", "state": "North Carolina" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Greenville", "state": "North Carolina" }, { "city": "Hendersonville", "state": "North Carolina" }, { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01137825" } ] }